The American journal of cardiology
-
Cardiac pacing remains one of the most effective means for preventing torsade de pointes in patients with long QT syndrome (LQTS). However, fatal arrhythmias may occur despite combined therapy with beta blockers and pacing, and it is possible that failure of cardiac pacing for preventing arrhythmias in the long run is related (at least in part) to suboptimal pacemaker programming. ⋯ Unfortunately, properly functioning pacemakers cannot be expected to prevent postextrasystolic pauses. The use of a pause-prevention pacing algorithm-rate smoothing-for preventing pause-dependent torsade de pointes is described in 12 patients with cardiac arrest or syncope due to congenital LQTS who were followed for 21 +/- 11 months.
-
Data from 2 decades of clinical electrophysiologic studies have allowed great progress in the evaluation and treatment of patients with sustained ventricular arrhythmias and the appropriate identification of those patients at high risk for subsequent sudden death. The goals of treatment of the patient with ventricular arrhythmias are to suppress symptoms and prevent a fatal event. ⋯ Although low-risk groups may benefit from reassurance or medications such as beta-blockers or verapamil, high-risk groups have been more difficult to treat. Recent randomized trials of implantable cardioverter defibrillators (ICDs) for ventricular arrhythmias suggest that they may provide better protection for high-risk patients than do antiarrhythmic medications.
-
Although atrial fibrillation is the most common sustained arrhythmia that requires medical attention, it remains a challenge to treat. Nevertheless, considerable progress has been made toward developing curative, catheter-based treatments for selected patients with atrial fibrillation. The most significant clinical observation during electrophysiologic testing in patients with atrial fibrillation has been a recognition of the importance of the pulmonary veins for the initiation of this arrhythmia. ⋯ In addition, ablation strategies that are designed to electrically isolate the pulmonary veins from the bulk of the left atrium are likely to lead to improvements in the long-term outcome of ablation. For patients with permanent atrial fibrillation, considerable progress has been made in the restoration of sinus rhythm by linear ablation strategies in the left atrium. It is likely that a comprehensive nonpharmacologic treatment for atrial fibrillation will incorporate the lessons learned from each of these approaches and lead to a genuine cure of this vexing arrhythmia.
-
Antiarrhythmic drugs, mainly amiodarone and sotalol, radiofrequency catheter ablation, and the implantable cardioverter defibrillator (ICD) are the 3 therapeutic options in patients with sustained ventricular tachycardia (VT) or ventricular fibrillation (VF). Idiopathic VT, incessant VT, frequently recurring, hemodynamically stable VT, and VT based on bundle branch reentry, are candidates for radiofrequency catheter ablation. Patients with high-risk ventricular tachyarrhythmias should receive ICDs as initial therapy. ⋯ The problem in the CIDS trial in this regard was the recruitment of patients in whom the inclusion criteria were met by the arrhythmias induced during the electrophysiology stimulation study, but which did not exist in real life. In addition CIDS included 14% of patients with (1) undocumented syncope and inducible monomorphic sustained VT; or (2) long runs of spontaneous nonsustained VT. Under these circumstances, the therapeutic implications of AVID remain unchallenged.